Seven out of eight RUNX1-mutant AML patients (88%) with PB blasts detectable at screening had a reduction in peripheral blasts during the first cycle of treatment with BTX-A51 (Fig. 3A). This evidence concerns the gene RUNX1 and acute myeloid leukemia.